新型左甲状腺素溶液在高脂高热量餐前30分钟或仅15分钟服用的生物利用度相似
该随机研究纳入36名健康志愿者(33名完成),单次口服600 mcg新型左甲状腺素溶液,分别于高脂高热量标准餐前15分钟或30分钟服用,采用液相色谱-串联质谱法测定血清总甲状腺素。结果显示AUC0-48几何均值比90%(90%CI 86-94)、AUC0-72为92%(90%CI 87-97),均在预设等效界值80-125%内,Cmax为85%(90%CI 80-90),两组中位tmax均为1.5小时,不良事件发生率相似。结论认为餐前15分钟与30分钟服用的药代动力学无显著差异,但需进一步研究其他时间点及真实世界有效性。
要点
- 新型左甲状腺素溶液餐前15分钟与30分钟服用的AUC和Cmax均在预设等效界值80-125%内。
- 两组中位达峰时间均为1.5小时,不良事件发生率相似。
- 作者认为需进一步研究其他时间点(包括餐前即刻)的生物利用度及真实世界有效性。
核心结论
- 在健康受试者中,新型左甲状腺素溶液在高脂高热量餐前15分钟与30分钟服用,药代动力学性质无显著差异。
研究设计与样本
- 随机研究,36名健康志愿者(33名完成,24名男性、9名女性),单次口服600 mcg左甲状腺素溶液,分别于10小时禁食后、高脂高热量FDA批准标准餐前15分钟或30分钟服用,清洗期至少35天。
主要发现
- 基线校正的AUC0-48几何均值比为90%(90%CI 86-94),AUC0-72为92%(90%CI 87-97),均在预设等效界值80-125%内。
- 基线校正的Cmax几何均值比为85%(90%CI 80-90)。
- 两组中位tmax均为1.5小时,不良事件发生率相似。
关键数值与推荐
- 预设等效界值为暴露量AUC的80-125%。
- AUC0-48几何均值比90%(90%CI 86-94),AUC0-72为92%(90%CI 87-97),Cmax为85%(90%CI 80-90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究其他时间点(包括餐前即刻)的整体生物利用度差异。
- 作者指出需进一步研究该制剂在新给药条件下的真实世界有效性,以优化甲状腺功能减退患者的治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Levothyroxine (LT4) sodium is a standard treatment for hypothyroidism. Its absorption and bioavailability when taken as a tablet have been shown to be significantly decreased with concomitant food ingestion. Therefore, LT4 formulations are recommended to be taken on an empty stomach, at least 30, ideally 60, minutes before breakfast, potentially affecting adherence to therapy. A novel LT4 solution (Tirosint®-SOL) has been shown to result in a faster absorption process than tablets or soft-gel capsule formulations. The objective of this trial was to evaluate the bioavailability of this preparation taken 15 minutes before a high-fat high-calorie meal in comparison with the minimally recommended 30-minute interval. Methods: Thirty-six (33 completers, 24 males and 9 females) healthy volunteers participating in the randomized study took 600 mcg of LT4 oral solution, single doses after a 10-hour fast, 15 or 30 minutes before a high-fat, high-calorie, FDA-approved standardized meal in a controlled research setting. We measured serum total thyroxine using Liquid Chromatography with Tandem Mass Spectrometry at baseline and multiple time points up to 72 hours after LT4 administration. The predefined equivalence boundaries for the extent of exposure reflected by the area under the curve (AUC) were 80-125%. The washout period was at least 35 days. Results: The geometric mean ratios and confidence intervals (CIs) for the baseline-adjusted extent of exposure represented by AUCs truncated at both 48 and 72 hours after dosing (AUC0-48: 90% [90% CI 86-94]; and AUC0-72: 92% [90% CI 87-97]) were within the prespecified equivalence boundaries. The baseline-adjusted peak concentration was also clinically similar (Cmax: 85% [90% CI 80-90]). The median tmax was 1.5 hours in each group. The rate of adverse events was similar between groups. Conclusions: We observed no significant difference in the pharmacokinetic properties of a novel LT4 solution administered 15 and 30 minutes before a high-fat high-calorie meal in normal subjects. Further research is needed to evaluate (a) the differences in overall bioavailability at other time points (including immediately premeal) and (b) the real-world effectiveness of this preparation in newly proposed administration conditions to optimize treatment outcomes in hypothyroid patients.
引用
- Ducharme M, Scarsi C, Bettazzi E, et al. A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes Before a High-Fat High-Calorie Meal. Thyroid. 2022. PMID: 35469428. doi:10.1089/thy.2021.0604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。